Common Stock
Ticker symbol: BMY
New York Stock Exchange

Stockholder Services
All inquiries concerning stockholder accounts and stock transfer matters – including address changes, the elimination of duplicate mailings and the Shareowner Services Plus Plan℠ – should be directed to the Company’s Transfer Agent and Registrar:
EQ Shareowner Services
1110 Centre Pointe Curve, Suite 101
Mendota Heights, MN 55120-4100
www.shareowneronline.com
855-598-5485 (within the U.S.)
651-450-4064 (outside the U.S.)
A telecommunications relay service should be used by the hearing impaired when calling the telephone numbers above.

Shareowner Services Plus Plan℠
The Shareowner Services Plus Plan℠ is designed for long-term investors who wish to build share ownership in the Company’s common stock over time. You can participate in the plan if you are a registered holder of the Company’s common stock. If you do not own the Company’s common stock, you can become a participant by making your initial purchase through the plan. The plan features dividend reinvestment, optional cash purchase, share safekeeping, and share sales and transfers. Bristol-Myers Squibb Company has appointed EQ Shareowner Services as Administrator for the plan. The plan is not sponsored or administered by Bristol-Myers Squibb Company.

Form 10-K
For a free copy of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, contact:
Corporate Secretary
Bristol-Myers Squibb Company
430 E. 29th Street, 14FL
New York, NY 10016
The Form 10-K is also available at investor.bms.com.
The most recent certifications by the Company’s chief executive officer and chief financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 are filed as exhibits to the Company’s Form 10-K. The Company has also filed with the New York Stock Exchange the most recent Annual CEO Certification as required by Section 303A.12(a) of the New York Stock Exchange Listed Company Manual.

Additional Information
Information on the following subjects is available at www.bms.com:
- Bristol-Myers Squibb Foundation
- Clinical Trials
- Compliance and Ethics
- Diversity and Workforce Statistics
- Patient Assistance Programs
- Policy and Advocacy Engagement and Political Contributions
- Sustainability/Environmental Programs

This Annual Report contains certain forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations and involve inherent risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations. Please see page 26 in the Financial Review for a discussion and description of these risks and uncertainties. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Product Names and Company Programs
Global products and company program names appearing throughout in italics are referred to herein by their registered and approved U.S. trademarks, unless specifically noted otherwise.
Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd.
Adcetris is a trademark of Seattle Genetics, Inc.
Atripla, Truvada, and Tybost are trademarks of Gilead Sciences, Inc. and/or one of its affiliates.
Avapro/Avalide (known in the EU as Aprovel/Karvea) and Plavix are trademarks of Sanofi
Byetta is a trademarks of Amylin Pharmaceuticals, LLC
ENHANZE is a trademark of Halozyme, Inc.
Eribulin is a trademark of ImClone LLC
Farxiga and Onglyza are trademarks of AstraZeneca AB
Gleevec is a trademark of Novartis AG
Ixempra is a trademark of R-Pharm US Operating, LLC
Keytruda is a trademark of Merck Sharp & Dohme Corp.
Prostvac is a trademark of BN ImmunoTherapeutics Inc.
SECURE THE FUTURE is trademark of Bristol-Myers Squibb.
Brand names of products that are in all italicized letters, without an asterisk, are registered trademarks of Bristol-Myers Squibb and/or one of its subsidiaries.